No abstract

Introduction and Aim: Multiple Multiple sclerosis (MS) is a complex neurological condition  might emerge as a result ofcomplex combination of genetic risk factors with environmental triggers, including oxidative stress. in this study we aimed to evaluate the effects of oral Crocin on oxidative stress in patients with MS.  Materials and Methods: Adjunct to standard treatment, the Crocin group (20 patients) received 30-mg/day (15 mg twice daily) dose of Crocin and placebo group (20 patients) received for 4 weeks. Saliva and urine samples were collected to determine the levels of total antioxidant capacity (TAC), catalase activity (CAT), total thiol groups (TTG), lipid peroxidation (LPO), were measured at baseline and the end of the study.   Results: At baseline, there were no significant differences of LPO, TAC, CAT, and TTG of urine between the control and case groups. However, a significant difference was found after 4 weeks of Crocin-therapy in TTG,TAC and LPO (p<0.05) except in CAT activity (P>0.05). We found no deffrence in urinary TTG level and CAT activity in control group at the end of intervention (P>0.05), while TAC and LPO level were significantly different at the end of the study as compared with the beginning (P<0.05). Althugh, we found no significant difference in saliva LPO, TTG and TAC levels and the activity of CAT in case and control groups at first (p>0.05), Crocin administration have resulted in a significant increase in saliva TTG and TAC levels as well as CAT activity and markedly decrease in LPO level (p<0.05). Conclusion: According to the results of this study, Crocin can significantly reduce the several oxidative stress factors in MS patients and may contributes to attenuates the oxidative damages.

Background and Objective. There is a growing body of evidence for the efficacy of oleoylethanolamide (OEA) in patients with inflammatory disorders. The present randomized double-blind placebo-controlled study is aimed at evaluating the efficacy of OEA add-on treatment in patients with acute ischemic stroke (AIS). Methods. Sixty patients with a mean age of 68.60 ± 2.10 comprising 29 females (48.33%), who were admitted to an academic tertiary care facility within the first 12 hours poststroke symptoms onset or last known well (LKW), in case symptom onset time is not clear, were included in this study. AIS was confirmed based on a noncontrast head CT scan and also neurological symptoms. Patients were randomly and blindly assigned to OEA of 300 mg/day ( n = 20 ) or 600 mg/day ( n = 20 ) or placebo ( n = 20 ) in addition to the standard AIS treatment for three days. A blood sample was drawn at 12 hours from symptoms onset or LKW as the baseline followed by the second blood sample at 72 hours post symptoms onset or LKW. Blood samples were assessed for inflammatory and biochemical parameters, oxidative stress (OS) biomarkers, and lipid profile. Results. Compared to the baseline, there is a significant reduction in the urea, creatinine, triglyceride, high-density lipoprotein, cholesterol, alanine transaminase, total antioxidant capacity, malondialdehyde (MDA), total thiol groups (TTG), interleukin-6 (IL-6), and C-reactive protein levels on the follow-up blood testing in the OEA (300 mg/day) group. In patients receiving OEA (600 mg/day) treatment, there was only a significant reduction in the MDA level comparing baseline with follow-up blood testing. Also, the between-group analysis revealed a statistically significant difference between patients receiving OEA (300 mg/day) and placebo in terms of IL-6 and TTG level reduction when comparing them between baseline and follow-up blood testing. Conclusion. OEA in moderate dosage, 300 mg/day, add-on to the standard stroke treatment improves short-term inflammatory, OS, lipid, and biochemical parameters in patients with AIS. This effect might lead to a better long-term neurological prognosis.

Aim: The prevalence of human parvovirus B19 (B19V) and its association with other diseases in Iran are yet to be systematically assessed. This study aimed to evaluate the prevalence and disease association of B19V across Iran from 2000 to 2019. Methods: The literature search, based on different keywords in different databases, was performed. A total of 29 eligible studies were included and the essential information was collected from each article. Results: The results of this study show a relatively high prevalence of the B19V-associated diseases in all age groups of the Iranian population. Conclusion: The transmission of B19V and its complications should be prevented by developing preventative strategies.